Company: AZN
Filing Date: 2025-10-20
Form Type: 6-K
Source: 0001654954-25-011943
Chunk: 4

Company: ASTRAZENECA PLC
Filing Date: 2025-10-20
Form: 6-K
Chunk 4
---
-changing medicines that help eliminate COPD as a leading cause of death, eliminate asthma attacks and achieve clinical remission in immune-mediated diseases.

#### AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca .

#### Contacts
For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

#### References
1. AstraZeneca. Saphnelo self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis. Available at: Saphnelo self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis . [Last accessed: October 2025].

2. Furie R, et al. What does it mean to be a British Isles Lupus Assessment group-based composite lupus assessment responder? Post hoc analysis of two phase III trials. Arthritis Rheumatol . 2021;73:2059-2068.

3. Morand E, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med . 2020;382(3):211-221.

4. Furie R, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol . 2019;1(4):e208-e219.

5. Furie R, et al. Anifrolumab, an anti-interferon ‐ a receptor monoclonal antibody, in moderate ‐ to ‐ severe systemic lupus erythematosus. Arthritis Rheumatol . 2017;69(2):376-386.

6. Tian J, et al. Global epidemiology of systemic lupus